The EGFR-Multiplex 5% AF cfDNA in Plasma is a specialized product designed to facilitate critical advancements in cancer research and diagnostics. EGFR (Epidermal Growth Factor Receptor) mutations are recognized as major driver mutations, notably contributing to the development of lung and breast cancers. Understanding and detecting these mutations are essential for effective cancer treatment strategies, particularly for Non-Small Cell Lung Cancer (NSCLC).

Our EGFR-Multiplex 5% AF cfDNA in Plasma includes a comprehensive selection of mutations. It encompasses both TKI (tyrosine kinase inhibitor) sensitive and resistant mutations, which are of significant clinical importance for NSCLC therapy. By incorporating these mutations, this product supports precise therapy selection and monitoring of therapeutic resistance, optimizing treatment outcomes for patients.

This high-quality reference material is engineered for use in diverse applications. Laboratories and research facilities can utilize the EGFR-Multiplex 5% AF cfDNA in Plasma as a reliable positive control standard in liquid biopsy assays. It is instrumental for validating EGFR diagnostic kits and in the development and fine-tuning of new assay methodologies. The cfDNA originates from the Ashkenazim Son cell line, integrated with human-tech plasma, providing consistency and relevance for real-world diagnostic needs.

Whether used in a clinical lab or an R&D environment, the EGFR-Multiplex 5% AF cfDNA in Plasma ensures that your liquid biopsy assays are backed by robust, clinically relevant materials. Leverage this product for the reliable detection and analysis of EGFR mutations, and make strides in the effective diagnosis and treatment of cancer.